[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thymoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thymoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,77,104,137,160,181,205,231,264,288],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100205406","tissue-procurement-and-natural-history-study-of-patients-with-malignant-mesothelioma-100205406",false,"NCT01950572","Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma","Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers","* INCLUSION CRITERIA:\n* All participants \\>= 2 years of age with malignant mesothelioma.\n* All participants \\>=18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin.\n* Confirmed pathological diagnosis is required\n* Ability and willingness of participant to provide informed consent to participation.\n\nEXCLUSION CRITERIA:\n\n* Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.\n* Pregnant women.\n* Active concomitant medical or psychological illnesses that may increase the risk to the participant or in adult participants, inability to obtain informed consent, at the discretion of the principal investigator.","ALL","2 Years","100 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis.\n* Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States.\n* The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis.\n* Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease.\n* In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma.\n\nObjectives:\n\n-To allow sample acquisition for use in the study of mesothelioma.\n\nEligibility:\n\n* All participants age greater than or equal to 2 years with malignant mesothelioma OR\n* All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin\n* Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18\n\nDesign:\n\n* Up to 1000 subjects will be enrolled.\n* Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma.\n* Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking.\n* Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.",[25,26,27,28,29,30],"Thymoma","Stomach Neoplasms","Pancreatic Neoplasms","Mesothelioma","Biliary Tract Neoplasms","Mesothelin Expressing Neoplasms",[32,33,34,35,36],"Samples","Biobank","Lung Neoplasms","Ovarian Neoplasms","Natural History","RECRUITING","2026-06-24",{"date":40,"type":41},"2026-06-25","ACTUAL",{"date":43,"type":41},"2013-09-09",{"name":45,"class":46},"National Cancer Institute (NCI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100636887","thymic-disease-autoimmunity-and-neuromuscular-junction-integrity-in-myasthenia-gravis-100636887","NCT07571525","Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis","Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis: An Observational Prospective Translational Cohort Study","TAILOR-MG","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent\n* Ability to provide written informed consent and comply with study procedures\n* Availability of a serum sample for testing MG-related antibodies\n* Availability of chest imaging (CT and\u002For MRI) to classify thymic status\n\nParticipants must also meet the criteria for at least one of the following study groups:\n\nCohort 1: Thymoma with MG-related antibodies\n\n* Histologically or radiologically confirmed thymoma\n* Presence of at least one pathogenic MG-related antibody (AChR)\n* Presence or absence of clinically manifest myasthenia gravis\n\nCohort 2: Other thymic abnormalities with MG-related antibodies\n\n* Imaging or histological evidence of non-thymomatous thymic pathology (e.g., thymic hyperplasia)\n* Presence of at least one pathogenic MG-related antibody (AChR)\n* Presence or absence of clinically manifest myasthenia gravis\n\nCohort 3: Thymoma without MG-related antibodies\n\n* Histologically or radiologically confirmed thymoma\n* Negative for pathogenic MG-related antibodies (AChR)\n* No clinical diagnosis or symptoms suggestive of myasthenia gravis\n\nCohort 4: Myasthenia gravis without thymic abnormalities\n\n* Established clinical diagnosis of myasthenia gravis with consistent clinical features, supported by at least one of the following:\n\n  1. Seropositivity for MG-related antibodies (AChR, MuSK, or LRP4), or\n  2. Abnormal neuromuscular transmission demonstrated by SFEMG or RNS, or\n  3. Improvement of MG signs with treatment such as oral acetylcholinesterase inhibitors, plasma exchange, IVIg, or corticosteroids\n* Absence of thymic abnormalities on CT or MRI\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Other neuromuscular diseases that could interfere with interpretation of clinical or neurophysiological findings\n* Severe uncontrolled systemic illness that, in the investigator's judgment, may limit participation or confound study outcomes\n* Any medical or psychiatric condition, or history of substance abuse, that may compromise adherence to study procedures\n* Pregnancy or breastfeeding","18 Years",{"count":58,"type":21},40,"The goal of this observational study is to investigate the clinical, immunological, and neuromuscular features associated with the development and progression of myasthenia gravis (MG) in adult patients with thymic abnormalities and\u002For MG-related antibodies, including individuals with or without clinically manifest disease.\n\nThe main questions it aims to answer are:\n\n* Whether integrated clinical, serological, and histopathological profiles are associated with the presence of MG and can predict disease onset or progression\n* Wheter systemic immune markers are associated with disease activity, progression, and neuromuscular junction alterations\n\nParticipants will:\n\n* Undergo clinical, neurological, and neurophysiological assessments at baseline and during follow-up\n* Provide blood samples for serological and immunological analyses\n* Provide thymic tissue and residual intercostal muscle samples (when undergoing clinically indicated thymectomy) for research analyses\n* Attend follow-up visits at 6, 12, and 18 months\n* Record daily symptoms using an electronic patient-reported outcome tool (for participants with MG)",[61,62,25],"Myasthenia Gravis (MG)","Myasthenia Gravis Associated With Thymoma",[64,65],"myasthenia gravis","thymoma","NOT_YET_RECRUITING","2026-04-30",{"date":69,"type":41},"2026-05-06",{"date":71,"type":21},"2026-09-15",{"date":73,"type":21},"2029-12-01",{"name":75,"class":76},"IRCCS San Raffaele","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":47},"100257691","adjuvant-radiotherapy-for-stage-iiiii-thymoma-after-complete-resection-100257691","NCT02633553","Adjuvant Radiotherapy for Stage II\u002FIII Thymoma After Complete Resection","An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II\u002FIII Thymoma After Complete Resection","Inclusion Criteria:\n\n18\\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent.\n\nExclusion Criteria:\n\nPatients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.","75 Years",{"count":86,"type":21},238,"INTERVENTIONAL",[89],"NA","This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.",[25],[65,93,94],"adjuvant radiotherapy","complete resection","2026-04-22",{"date":97,"type":41},"2026-04-24",{"date":99,"type":41},"2018-01-10",{"date":101,"type":21},"2029-12",{"name":103,"class":76},"Fudan University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":115,"studyType":22,"phases":4,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":47},"100618165","electrocautery-resection-combined-with-hithoc-for-thymic-epithelial-tumors-with-pleural-metastasis-100618165","NCT07328074","Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis","Prospective Cohort Study of Electrocautery Resection Combined With Hyperthermic Intrathoracic Chemotherapy for Thymic Epithelial Tumors With Pleural Metastasis","Inclusion Criteria:\n\n* Pathologically confirmed thymic epithelial tumor (TET)\n* Imaging evidence of thymic epithelial tumor with pleural dissemination or recurrence, deemed suitable for HITHOC by multidisciplinary thoracic team\n* Age ≥16 years and ≤80 years\n* American Society of Anesthesiologists (ASA) physical status classification I-II\n* Normal major organ function\n* No history of other malignancies\n* Prior chemotherapy completed \\>4 weeks, radiotherapy \\>6 weeks, immunotherapy \\>6 weeks before enrollment\n* No allergy to cisplatin or doxorubicin\n* Able to understand the study content and provide informed consent\n\nExclusion Criteria:\n\n* Evidence of extrathoracic metastasis on imaging or pathological examination\n* Myasthenia gravis in unstable phase or acute exacerbation\n* Severe systemic comorbidities, such as active infection, poorly controlled diabetes, coagulopathy, bleeding tendency, or ongoing thrombolytic\u002Fanticoagulation therapy\n* Positive serum pregnancy test or lactation (females)\n* History of organ transplantation (including autologous bone marrow transplantation and peripheral blood stem cell transplantation)\n* History of peripheral nervous system disease, significant psychiatric disorder, or central nervous system disease\n* Currently participating in other clinical trials","16 Years","80 Years",{"count":114,"type":21},70,"36 Months","The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or recurrence. The study aims to:\n\n* Evaluate whether this combined treatment improves event-free survival in patients with pleural metastasis from thymic epithelial tumors\n* Assess the rates of grade ≥3 treatment-related adverse events\n* Examine how this treatment affects patients' quality of life\n\nParticipants will:\n\n* Undergo extended thymectomy with electrocautery resection of pleural metastases\n* Receive two cycles of hyperthermic intrathoracic chemotherapy with cisplatin and doxorubicin at 42-43°C, 2-4 days apart\n* Complete quality of life questionnaires (EQ-5D) at baseline and regular intervals\n* Have regular follow-up visits with imaging and clinical assessments for up to 36 months to monitor for disease recurrence or progression",[118,25,119,120,121],"Thymic Epithelial Tumor","Thymic Carcinoma","Pleural Metastasis","Pleural Recurrence",[123,124,125,126,127],"Hyperthermic Intrathoracic Chemotherapy","HITHOC","Electrocautery","Cisplatin","Doxorubicin","2026-02-02",{"date":130,"type":41},"2026-02-05",{"date":132,"type":21},"2026-02",{"date":134,"type":21},"2031-02",{"name":136,"class":76},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":87,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100535183","phase-2-a-phase-ii-trial-of-sacituzumab-govitecan-in-patients-with-advanced-thymic-epithelial-tumors-100535183","NCT06248515","A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors","A Phase II Parallel Arm Study of SACITUZUMAB GOVITECAN-HZIY in Patients With Advanced Thymoma and Thymic Carcinoma","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years at time of signing informed consent form (ICF)\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients with histologically confirmed advanced thymoma or thymic carcinoma\n* Patients who have experienced disease progression after treatment with at least one prior systemic therapy\n* Measurable disease per RECIST v1.1\n* Availability of pre-treatment tumor tissue (archival or fresh); If archival tissue is not available and a fresh biopsy is not considered safe and medically feasible by the Investigator, the patient may be approved for enrollment after consultation with the Principal Investigator\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:\n* Absolute neutrophil count (ANC) \\>\u002F= 1.5 x 10\\^9\u002FL (1500\u002FuL) without filgrastim support\n* Platelet count \\>\u002F= 100 x 10\\^9\u002FL (100,000\u002FuL) without transfusion\n* Hemoglobin (Hgb) \\>\u002F= 80 g\u002FL (8 g\u002FdL). Patients may be transfused to meet this criterion.\n* Aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) \\\u003C\u002F= 2.5 x upper limit of normal (ULN), with the following exceptions:\n\n  * Patients with documented liver metastases: AST and ALT \\\u003C\u002F= 5 x ULN\n  * Patients with documented liver or bone metastases: ALP \\\u003C\u002F= 5 x ULN Serum bilirubin \\\u003C\u002F= 1.5 x ULN with the following exception: patients with known Gilbert disease: serum bilirubin \\\u003C\u002F= 3 x ULN\n* Creatinine clearance \\>\u002F= 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula, see Appendix 2)\n* For patients not receiving therapeutic anticoagulation: INR and aPTT \\\u003C\u002F= 1.5 x ULN\n* Patients with human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable or on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:\n\n  * Women must remain abstinent or use contraceptive methods with a failure rate of \\\u003C 1% per year during the treatment period and for 6 months after the final dose of study treatment. Women must refrain from donating eggs during this same period.\n  * A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (\\>\u002F= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.\n  * Examples of contraceptive methods with a failure rate of \\> 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\n\n  * With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C 1% per year during the treatment period and for 90 days after the final dose of sacituzumab govitecan-hziy. Men must refrain from donating sperm during this this same period.\n  * With a pregnant female partner, men must remain abstinent or use a condom during the treatment period and 90 days after the final dose of sacituzumab govitecan-hziy to avoid potential exposure to the embryo.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.\n\nExclusion Criteria:\n\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the view of the investigator, contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 6 months after the final dose of study treatment.\n* Symptomatic brain metastasis requiring corticosteroids. Patients with treated brain metastases are eligible.\n* No concurrent therapy with approved or investigational anticancer therapeutics",{"count":145,"type":21},18,[147],"PHASE2","The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy.\n\nThe main question it aims to answer is:\n\n• What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma?\n\nParticipants will:\n\n* receive a fixed dose of 10 mg\u002Fkg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity\n* have regular blood tests, scans, and examinations to monitor their health.\n* have blood and a biopsy of their tumor for research purposes.",[25,119],"2026-01-23",{"date":152,"type":41},"2026-01-27",{"date":154,"type":41},"2024-04-25",{"date":156,"type":21},"2026-12",{"name":158,"class":76},"Georgetown University",4,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":167,"targetDuration":4,"studyType":87,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":47},"100580562","phase-2-tislelizumab-combined-with-anlotinib-as-second-line-therapy-in-thymoma-and-thymic-carcinoma-100580562","NCT06838910","Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma","Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma: An Open-label, Single-centre, Phase 2 Study","Inclusion Criteria:\n\n1. Age 18-75 years old, gender is not limited.\n2. Histologically or cytologically confirmed thymoma or thymic carcinoma.\n3. Disease progression during or after first-line chemotherapy (with or without immunotherapy).\n4. At least one measurable solid tumor lesion according to RECIST 1.1 criteria.\n5. Estimated survival ≥ 3 months; United States Eastern Cooperative Oncology Group (ECOG) score: 0 or 1 point.\n6. Vital organ function meets the following criteria:\n\n   1. Hematological examination (no use of any blood components and cell growth factors within 14 days prior to initiation of study treatment): i. neutrophil count (ANC) ≥ 1.5×109\u002FL; ii. platelet count (PLT) ≥100 × 109\u002FL; iii. hemoglobin (Hb) ≥80g\u002FL;\n   2. total bilirubin (TBIL) ≤ 1.5× upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× ULN, serum albumin (ALB) ≥28g\u002FL;\n   3. left ventricular ejection fraction (LVEF) ≥50%;\n7. Female subjects of childbearing potential must have a serum pregnancy test within 7 days prior to the first dose with a negative result; and must be non-lactating; Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to comply with contraceptive requirements from the time of signing the informed consent form until 8 weeks after the end of the last treatment session.\n8. Informed consent was signed.\n\nExclusion Criteria:\n\n1. Prior treatment with anlotinib or any other anti-angiogenesis drugs.\n2. Patients with symptomatic brain metastasis.\n3. Other primary malignancy in the past 5 years, with the exception of: (radical Non-melanoma skin cancer or cured cervical in-situ carcinoma).\n4. Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis.\n5. Severe infections within 4 weeks prior to inclusion.\n6. Any of the following severe acute comorbidities prior to inclusion:\n\n   1. Does not have uncontrolled pleural effusion\u002Fpericardial effusion\u002For ascites as determined by the investigator;\n   2. Unstable angina myocardial infarction or uncontrolled congestive heart failure within 12 months;\n   3. Uncontrollable hypertension;\n   4. Urine routine test protein ≥++, and confirmed 24 hours urine protein\\> 1.0 g;\n7. Imaging shows that the tumor has invaded a vital vessel perimeter or who, in the opinion of the investigator, have a high likelihood of fatal hemorrhage due to tumor invasion of a vital vessel during the follow-up study;\n8. Clinically significant hemoptysis (daily hemoptysis greater than 50ml) within 3 months prior to enrollment; or significant clinically significant bleeding symptoms or defined bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, or suffering from vasculitis;\n9. Major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to inclusion.\n10. Presence of any mental disease or drug abuse disorder that may interfere with subject's ability for being compliant with study requirements.\n11. Known hypersensitivity or allergy to monoclonal antibody.\n12. Is receiving systemic steroid therapy \\\u003C 2 weeks prior to the first dose of trial treatment or receiving any other form of immunosuppressive medication.\n13. Diagnosis of immunodeficiency or undergoing systemic glucocorticoid therapy or any other immunosuppressive therapy that was continued within 2 weeks prior to the first dose.\n14. Participation in another clinical trial within 28 days.\n15. Any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results.",{"count":168,"type":21},20,[147],"It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy. The purpose of this study is to evaluate the safety and efficacy of tislelizumab combined with anlotinib as second-line in thymoma and thymic carcinoma.",[119,25],"2025-11-24",{"date":174,"type":41},"2025-12-01",{"date":176,"type":41},"2025-03-31",{"date":178,"type":21},"2026-12-30",{"name":180,"class":76},"The First Affiliated Hospital with Nanjing Medical University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":188,"targetDuration":4,"studyType":87,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":47},"100572210","phase-2-glucocorticoids-combined-with-concurrent-chemoradiotherapy-for-unresectable-thymoma-100572210","NCT06730308","Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma","A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma","Inclusion Criteria:\n\n* Histologically confirmed type AB or B1-3 thymoma.\n* Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).\n* Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.\n* Between the ages of 18 and 70 years, regardless of sex.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* No prior chest radiation.\n* Adequate organ Functions.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Contraindications to Methylprednisolone.\n* History of or Concurrent Malignancy.\n* Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.\n* Pregnant or Lactating Women.\n* Bleeding Disorders.\n* Recent Participation in Other Clinical Trials.\n* Drug Abuse or Severe Alcoholism.\n* Uncontrolled Seizures or Mental Disorders.\n* Severe Allergies or Specific Sensitivities.",{"count":189,"type":21},45,[147],"This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.",[25],[25,194,195],"Concurrent chemoradiotherapy","Methylprednisolone","2024-12-11",{"date":198,"type":41},"2024-12-12",{"date":200,"type":41},"2024-11-20",{"date":202,"type":21},"2028-11-19",{"name":204,"class":76},"Sun Yat-sen University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":212,"targetDuration":4,"studyType":87,"phases":214,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":47},"100569270","hypofractionated-radiotherapy-for-thymic-epithelial-tumors-100569270","NCT06692062","Hypofractionated Radiotherapy for Thymic Epithelial Tumors","A Prospective Study of Hypofractionated Radiotherapy for Thymic Epithelial Tumors","Inclusion Criteria:\n\n1. Patients must provide written informed consent.\n2. 18 years old ≤ age \\\u003C75 years old.\n3. Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data.\n4. Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ\n5. ECOG performance status 0-2.\n6. Expected survival time \\> 1 year.\n7. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.\n8. Patients who are not lactating.\n9. Sufficient bone marrow reserve and good function of important organs.\n\nExclusion Criteria:\n\n1. patients with prior thoracic radiotherapy;\n2. diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure;\n3. Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care\n4. Patients with other malignant tumors that are not under stable control;\n5. Known history of mental illness, substance abuse, alcohol or drug abuse.\n6. Other conditions deemed unsuitable for enrollment by the attending physician.",{"count":213,"type":21},100,[89],"The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are:\n\n* Does Hypofractionated radiotherapy provide better results?\n* Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery.\n\nParticipants will:\n\n* Receive hypofractionated radiotherapy or conventional radiotherapy\n* Visit the hospital regularly once every 12 weeks for checkups and tests",[217,25,218,118],"Thymoma and Thymic Carcinoma","Thymic Cancer",[65,220,221],"hypofractionated radiotherapy","thymic carcinoma","2024-11-15",{"date":224,"type":41},"2024-11-18",{"date":226,"type":41},"2024-10-01",{"date":228,"type":21},"2027-11-01",{"name":230,"class":76},"Rongrong Zhou",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":239,"conditions":240,"keywords":252,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":47},"100455749","predictors-and-prognostic-factors-of-myasthenia-gravis-outcome-100455749","NCT05214612","Predictors and Prognostic Factors of Myasthenia Gravis Outcome","Inclusion Criteria:\n\n1. Age from 16 years and older.\n2. Gender: both sexes are included.\n3. Clinical Diagnosis of MG with supporting evidence as:\n\n   1. unequivocal clinical response to pyridostigmine\n   2. decrement \\>10% in repetitive nerve stimulations study (RNS).\n4. Willingness to sample collection, imaging study and other disease-related examinations and assessments.\n\nExclusion Criteria:\n\n1. Age younger than 16 years.\n2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.\n3. Severe systemic illness affecting life-expectancy.",{"count":238,"type":21},30,"This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG.\n\nThis information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.",[241,242,243,25,244,245,246,247,248,249,250,251],"Myasthenia Gravis","Autoimmune Diseases of the Nervous System","Neuromuscular Junction Diseases","Thymus Hyperplasia","Nervous System Diseases","Myasthenia Gravis, Generalized","Myasthenia Gravis, Ocular","Myasthenia Gravis Crisis","Myasthenia Gravis With Exacerbation (Disorder)","Myasthenia Gravis, Adult Form","Myasthenia Gravis, Juvenile Form",[253,254,241,255],"Predictors","Prognostic factors","Outcome","2024-07-30",{"date":258,"type":41},"2024-07-31",{"date":260,"type":41},"2022-01-01",{"date":176,"type":21},{"name":263,"class":76},"Assiut University",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":47},"100539292","artificial-intelligence-prediction-tool-in-thymic-epithelial-tumors-100539292","NCT06301945","Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors","Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors","INTHYM","Inclusion Criteria:\n\nParticipants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:\n\n* Thymoma A\n* Thymoma AB\n* Thymoma B1\n* Thymoma B2\n* Thymoma B3\n* Thymic Carcinoma\n\nInclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.\n\nRecurrence Criteria:\n\nParticipants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.",{"count":273,"type":21},1020,"Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and\u002For more aggressive subtypes, defined by the WHO histopathological classification.\n\nIn this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.\n\nThe investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.\n\nIn this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.\n\nThe ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.",[118,119,25,217],[277,278],"Artificial Intelligence","Digital pathology","2024-03-26",{"date":281,"type":41},"2024-03-27",{"date":283,"type":41},"2023-08-01",{"date":285,"type":21},"2027-08-01",{"name":287,"class":76},"Erasmus Medical Center",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":295,"targetDuration":4,"studyType":87,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":309},"100518367","robot-assisted-vs-vats-for-thymoma-100518367","NCT06029621","Robot-assisted vs VATS for Thymoma","Comparison of Short-term and Longterm Outcomes Between Robot-assisted Thoracoscopy and Television-assisted Thoracoscopy Surgery Forthymoma : a Multicenter, Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. ) The age of the subjects on the day of signing the informed consent was ≥ 18 years old and \\\u003C 75 years old, regardless of gender ;\n2. ) Chest thin-layer CT and MR showed anterior mediastinal space-occupying lesions, combined with relevant hematological indicators, the patient was clinically diagnosed as a thymic epithelial tumor with or without myasthenia gravis ( MG ) symptoms.\n3. ) need to accept thymectomy surgery ;\n4. ) Clinical stage I to IIIA ( AJCC-UICC TNM staging system ) ;\n5. ) The maximum diameter of the lesion \\\u003C 5cm ;\n6. ) physical condition score 0 or 1 ( Eastern Cooperative Oncology Group ECOG scoring system ) ;\n7. ) Have not received any anti-thymoma therapy before, including but not limited to systemic chemotherapy, radiotherapy, etc. ;\n8. ) Preoperative major organ function meets the following criteria : Bone marrow function: hemoglobin ≥ 10.0 g \u002F dL ( no blood transfusion within 28 days before hemoglobin examination ), absolute neutrophil count ≥ 1.5 × 109 \u002F L, platelet count ≥ 100 × 109 \u002F L ( no transfusion of apheresis platelets or IL-11 treatment within 14 days before platelet count examination ) ; coagulation function : INR and PT \\\u003C 1.5 × ULN, APTT ≤ 1.5 × ULN ; liver function: transaminase ( ALT and AST ) ≤ 2.5 × ULN; total bilirubin ≤ 1.5 × ULN ( Gilbert's syndrome or liver metastasis subjects total bilirubin ≤ 2.5 × ULN ) ; renal function: serum creatinine clearance rate ≥ 60 mL\u002Fmin ( calculated according to the Cockcroft-Gault formula ) ;\n9. ) voluntarily participated in and were able to undergo robot-assisted or thoracoscopic thymectomy, and complied with the study follow-up plan.\n\nExclusion Criteria:\n\n1. ) Patients with myasthenia gravis crisis ;\n2. ) had undergone mediastinal surgery or cardiac surgery ;\n3. ) body mass index ( BMI ) ≥ 30 ;\n4. ) Patients with severe liver and kidney dysfunction ( ALT and\u002For AST more than three times the upper limit of normal, Cr more than the upper limit of normal ) ;\n5. ) combined with severe chronic lung diseases such as COPD, asthma, or interstitial lung disease ;\n6. ) suffering from uncontrolled heart, kidney, gastrointestinal, and infectious diseases and other complications ;\n7. ) patients with other malignant tumors or hematological diseases ;\n8. ) combined with chronic pain or preoperative use of opioid analgesics ;\n9. ) patients with thoracic deformity or combined with pectus carinatum and pectus excavatum ;\n10. ) have mental disorders, such as anxiety disorders ;\n11. ) pregnant and\u002For lactating women ;\n12. ) is currently participating in other interventional clinical studies.",{"count":296,"type":21},304,[89],"The aim of this study is to explore the advantages of robot-assisted thymectomy in long-term survival benefits and short-term clinical efficacy compared with video-assisted thoracoscopic thymectomy based on a multi-center, prospective, randomized controlled clinical trial.",[25],"2024-02-27",{"date":302,"type":41},"2024-02-29",{"date":304,"type":41},"2023-11-20",{"date":306,"type":21},"2030-09-19",{"name":308,"class":76},"Shanghai Pulmonary Hospital, Shanghai, China",2]